{"organizations": [], "uuid": "2c03ff6d0233cec6122d2aafb0c137618c8ca4b6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180117.html", "section_title": "Archive News &amp; Video for Wednesday, 17 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-strongbridge-announces-acquisition/brief-strongbridge-announces-acquisition-of-u-s-canadian-rights-to-macrilen-from-aeterna-zentaris-idUSASB0C17P", "country": "US", "domain_rank": 408, "title": "BRIEF-Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.171, "site_type": "news", "published": "2018-01-17T20:51:00.000+02:00", "replies_count": 0, "uuid": "2c03ff6d0233cec6122d2aafb0c137618c8ca4b6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-strongbridge-announces-acquisition/brief-strongbridge-announces-acquisition-of-u-s-canadian-rights-to-macrilen-from-aeterna-zentaris-idUSASB0C17P", "ord_in_thread": 0, "title": "BRIEF-Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris", "locations": [], "entities": {"persons": [{"name": "strongbridge", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}, {"name": "co", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "macrilen from aeterna zentaris", "sentiment": "negative"}, {"name": "strongbridge biopharma plc", "sentiment": "negative"}, {"name": "aeterna zentaris", "sentiment": "none"}, {"name": "biopharma plc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 17 (Reuters) - Strongbridge Biopharma Plc:\n* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ACQUISITION OF THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN) FROM AETERNA ZENTARIS\n* STRONGBRIDGE BIOPHARMA - ‍UNDER TERMS OF AGREEMENT, CO TO MAKE UPFRONT PAYMENT OF $24 MILLION TO AETERNA WITHIN 5 DAYS OF EFFECTIVE DATE OF AGREEMENT​\n* STRONGBRIDGE BIOPHARMA - LICENSE & ASSIGNMENT AGREEMENT ALSO PROVIDES CO WITH EXCLUSIVE LICENSE TO MANUFACTURE & COMMERCIALIZE MACRILEN IN U.S. & CANADA\n* STRONGBRIDGE BIOPHARMA PLC - STRONGBRIDGE EXPECTS TO COMMERCIALLY LAUNCH MACRILEN IN MID-YEAR 2018\n* STRONGBRIDGE BIOPHARMA PLC - ‍EXPANDS STRUCTURED FINANCING FACILITY WITH CRG TO SUPPORT ANTICIPATED COMMERCIAL LAUNCH OF MACRILEN IN MID-2018​\n* STRONGBRIDGE BIOPHARMA - AETERNA ZENTARIS WILL REMAIN RESPONSIBLE FOR A PEDIATRIC DEVELOPMENT PROGRAM TO SUPPORT REGULATORY SUBMISSION FOR MACRILEN APPROVAL\n* STRONGBRIDGE - ‍IN CONJUNCTION WITH MACRILEN DEAL, CO, CRG AMENDED EXISTING SENIOR CREDIT FACILITY TO INCREASE TOTAL POTENTIAL BORROWING TO $100 MILLION​\n* STRONGBRIDGE BIOPHARMA-CO SHARING OVERSIGHT AND PAYING FOR 70 PERCENT OF COST OF PEDIATRIC DEVELOPMENT PROGRAM OR ABOUT $4 MILLION OVER A 3-YEAR PERIOD​\n* STRONGBRIDGE - ‍UNDER AMENDED FACILITY, CO RETAINED OPTION TO BORROW ADDITIONAL $10 MILLION BASED UPON SOME CONDITIONS​\n* STRONGBRIDGE - ‍INTENDS TO USE UPFRONT PROCEEDS FROM SECOND BORROWING TO FUND ACQUISITON, COMMERCIALIZATION OF MACRILEN, CORPORATE PURPOSES​\n* STRONGBRIDGE BIOPHARMA - TERM OF LOAN UNDER CREDIT FACILITY REMAINS 6 YRS, ALTHOUGH INTEREST-ONLY PERIOD HAS BEEN EXTENDED BY 6 MONTHS TO DEC 31, 2020\n* STRONGBRIDGE BIOPHARMA- ‍AS CONDITION TO SECOND BORROWING, ISSUED WARRANTS WITH 7-YEAR TERM TO CRG TO BUY 1.2 MILLION SHARES AT EXERCISE PRICE OF $10.00PER SHARE Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-17T20:51:00.000+02:00", "crawled": "2018-01-18T16:23:58.028+02:00", "highlightTitle": ""}